Abstract: A method for determining wavefront shapes of a multi-spectral signal light beam from a single signal image acquisition of said multi-spectral signal beam, with a device including an optical assembly made at least of an optical mask and an imaging sensor, notably a matrix imaging sensor, for generating and recording intensity patterns of incident beams, by having these beams reflect on, or propagate through, the optical mask. The optical mask having the optical properties: i) to cause the intensity pattern to depend on the wavefront shape, so that a tilt applied to the wavefront shape results in a displacement amount of the intensity pattern, and ii) to produce uncorrelated intensity patterns over at least one surface area A of the imaging sensor, for a plurality of respective incident monochrome beams of different wavelengths having a same wavefront shape.

Abstract: The present disclosure is directed to an obstacle awareness device for vehicle systems. A threshold distance is set that identifies the range at which an obstruction interferes with fluid dynamics around and through at least one propulsion motor. One or more ranging sensors on the vehicle system detect relative position information of the obstruction when it is within the threshold distance. The relative position information is communicated to a controller, which adjusts a motor control signal to compensate for the obstruction interfering with the fluid dynamics around the at least one propulsion motor. The threshold distance may be defined by a three dimensional shape that encapsulated the vehicle system 100, and the three dimensional shape may change in shape or size with movement of the vehicle system.

Abstract: The present disclosure is directed to an obstacle awareness device for vehicle systems. A threshold distance is set that identifies the range at which an obstruction interferes with fluid dynamics around and through at least one propulsion motor. One or more ranging sensors on the vehicle system detect relative position information of the obstruction when it is within the threshold distance. The relative position information is communicated to a controller, which adjusts a motor control signal to compensate for the obstruction interfering with the fluid dynamics around the at least one propulsion motor. The threshold distance may be defined by a three dimensional shape that encapsulated the vehicle system 100, and the three dimensional shape may change in shape or size with movement of the vehicle system.

Abstract: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.

Abstract: The invention relates to a machine (1) for filling a plurality of containers (2) that are arranged in a display (3), said machine (1) including a rotatable dispensing member (4) that is designed for transferring a filling substance into the containers (2). Said machine is also characterized in that it includes a means (10) for rotating a display (3) so that the combination of the rotational movements of the dispensing member (4) and the display (3) makes it possible to correlate the dispensing member (4) with each container (2), with a view to filling the latter. The invention also relates to filling machines.

Abstract: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.

Abstract: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.

Abstract: Methods for screening for compounds that inhibit neurodegeneration are presented. Shedding of APP can be a useful marker for neurodegeneration and compounds that inhibit shedding of APP are useful as inhibitors of neurodegeneration. Such compounds may be useful in treatment and/or prevention of various neurological diseases, disorders and neuronal damage and may enhance growth, regeneration or survival of mammalian neuronal cells or tissue.

Abstract: Methods for screening for compounds that inhibit neurodegeneration are presented. Shedding of APP can be a useful marker for neurodegeneration and compounds that inhibit shedding of APP are useful as inhibitors of neurodegeneration. Such compounds may be useful in treatment and/or prevention of various neurological diseases, disorders and neuronal damage and may enhance growth, regeneration or survival of mammalian neuronal cells or tissue.

Abstract: The invention provides methods of identifying naïve T cells by expression of PTK7.

Abstract: The present invention provides methods and compositions related to CNS function and diseases.

Abstract: The invention relates to methods of increasing density of dendritic spines as a means to retain or improve cognition and to treat disorders associated with decreased dendritic spine morphology and a psychiatric disorder such as addiction and schizophrenia or a disorder associated with impaired cognition such as autism, Lett Syndrome, Tourette Syndrome, and Fragile-X Syndrome.

Abstract: The invention provides methods and compositions relating to vertebrate UNC-5 proteins which function as receptor proteins for netrins, a family of cell guidance proteins. The proteins may be produced recombinantly from transformed host cells from the disclosed vertebrate UNC-5 encoding nucleic acid or purified from human cells. The invention provides specific hybridization probes and primers capable of specifically hybridizing with the disclosed vertebrate unc-5 gene, vertebrate UNC-5-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

Abstract: Methods and compositions comprising DR6 antagonists for use in treating neurological disorders, including Alzheimer's disease, are provided. The DR6 antagonists include anti-APP antibodies, anti-DR6 antibodies, DR6 immunoadhesins and DR6 variants (and fusion proteins thereof) which enhance growth, regeneration or survival of mammalian neuronal cells or tissue.

Abstract: The present invention provides methods and compositions related to CNS function and diseases.

Abstract: The present invention relates generally to neural development and neurological disorders. The invention specifically concerns identification of novel modulators of the myelin-associated inhibitory system and various uses of the modulators so identified.

Abstract: The present invention provides methods and compositions related to CNS function and diseases.

Abstract: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.

Abstract: A non-volatile memory device includes a network of non-volatile memory cells, each comprising a floating-gate transistor, said network of cells being intended to store data in the form of a set of data words. The device includes a circuit which detects loss of charges stored in the cells and then reprograms the cells for which a loss of charges has been detected so as to restore the level of stored charges.

Abstract: The present invention relates to PLEXIND1 agonists and their use for the treatment of disorders associated with angiogenesis, including cancer.